<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE REGISTRANT'S BALANCE SHEET AS OF MARCH 31,2000 AND STATEMENT
OF OPERATIONS FOR THE YEAR ENDED MARCH 31,2000 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<CIK>                        0001053369
<NAME>                       elite pharmaceuticals, inc
<MULTIPLIER>                                   1
<CURRENCY>                                     DOLLARS

<S>                                            <C>
<PERIOD-TYPE>                                  YEAR
<FISCAL-YEAR-END>                              Mar-31-2000
<PERIOD-START>                                 APR-01-2000
<PERIOD-END>                                   Mar-31-2000
<EXCHANGE-RATE>                                1
<CASH>                                         3,937,217
<SECURITIES>                                   0
<RECEIVABLES>                                  0
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               4,847,617
<PP&E>                                         2,874,285
<DEPRECIATION>                                 394,958
<TOTAL-ASSETS>                                 9,162,383
<CURRENT-LIABILITIES>                          712,780
<BONDS>                                        2,885,000
                          0
                                    0
<COMMON>                                       88,555
<OTHER-SE>                                     5,476,048
<TOTAL-LIABILITY-AND-EQUITY>                   9,162,383
<SALES>                                        10,315
<TOTAL-REVENUES>                               10,315
<CGS>                                          0
<TOTAL-COSTS>                                  3,059,675
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             137,709
<INCOME-PRETAX>                                (2,976,192)
<INCOME-TAX>                                   200
<INCOME-CONTINUING>                            (2,976,392)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (2,976,392)
<EPS-BASIC>                                    (.35)
<EPS-DILUTED>                                  (.35)


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission